Corbus Pharmaceuticals Holdings (CRBP) Accounts Payables (2013 - 2025)

Corbus Pharmaceuticals Holdings' Accounts Payables history runs 13 years deep, the most recent figure standing at $2.2 million for Q4 2025.

• On a quarterly basis, Accounts Payables fell 53.72% year-over-year to $2.2 million in Q4 2025; TTM through Dec 2025 was $2.2 million, a 53.72% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, down 53.72% from the prior year.
• Accounts Payables eased to $2.2 million in Q4 2025 per CRBP's latest filing, from $2.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.8 million in Q4 2024 and bottomed at $1.2 million in Q2 2024.
• The 5-year median for Accounts Payables is $2.4 million (2021), against an average of $2.6 million.
• Across the five-year window, Accounts Payables tumbled 85.21% in 2021 and jumped 246.18% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $1.8 million in 2021, then rose by 21.98% to $2.2 million in 2022, then surged by 46.23% to $3.2 million in 2023, then jumped by 50.55% to $4.8 million in 2024, then sank by 53.72% to $2.2 million in 2025.
• Per Business Quant, the three latest CRBP Accounts Payables figures stand at $2.2 million (Q4 2025), $2.7 million (Q3 2025), and $4.0 million (Q2 2025).